Duktus bağımlı konjenital kalp hastalığı olan bir term yenidoğanda invajinasyon

Year 2013, Volume: 40 Issue: 1, 105 - 108, 01.03.2013

Banu Aydın Dilek Dilli Aysegül Zenciroğlu Derya Erdoğan İbrahim Karaman Mehmet Şah İpek Nurullah Okumuş

https://doi.org/10.5798/diclemedj.0921.2013.01.0233

Abstract

Prostaglandin E1 infüzyonu, duktus bağımlı konjenital kalp hastalığı olan yenidoğanlarda ameliyat edilinceye kadar duktusu açık tutmak amacıyla yaygın olarak kul­lanılmaktadır. Prostaglandin E1 yaşam kurtarıcı bir ilactır ancak ateş, apne, bradikardi, hipotansiyon, konvülziyon, ödem ve kortikal hiperostoz gibi birçok yan etkiye de yol açabilir. İlacın doz azaltmasına yanıt veren ishal dışın­da gastrointestinal sistemle ilgili önemli yan etkisi rapor edilmemektedir. Bu yazıda duktus bağımlı konjenital kalp hastalığı olan ve olasılıkla prostaglandin tedavisi ile te­tiklenen intestinal invajinasyon gelişen bir olgu sunuldu.

Keywords

Prostaglandin E1, yenidoğan, gast­rointestinal

Intussusception in a term newborn with duct-dependent congenital heart disease

Abstract

Prostaglandin E1 infusion is widely used to maintain pa­tency of ductus arteriosus in newborns with duct-depen­dent congenital heart disease until surgery. Prostaglandin E1 is a lifesaving drug, but it has many side effects includ­ing fever, apnea, bradycardia, hypotension, convulsion, edema, and cortical hyperostosis. The gastrointestinal tract has not been recognized as a major site of serious adverse effects of prostaglandin E1 infusion, although diarrhea is a well-recognized side effect that usually re­sponds to dose reduction. In this report, we present a case of intestinal intussusception presumably induced by prostaglandin therapy in a newborn with duct-dependent congenital heart disease.

Keywords

Prostaglandin E1, newborn, gastrointestinal

References

• Coceani F, Olley PM. The response of the ductus arteriosus to prostaglandins. Can J Physiol Pharmacol 1973;51:220-5.
• Heymann MA. Pharmacologic use of prostaglandin E1 in infant with congenital heart disease. Am Heart J 1981;101:837-43.
• Lewis AB, Freed MD, Heymann MA, Roehl SL, et al. Side effects of therapy with prostaglandin E1 in infants with crit- ical congenital heart disease. Circulation 1981;64:893-8.
• Peled N, Dagan O, Babyn P, et al. Gastric-outlet obstruc- tion induced by prostaglandin therapy in neonates. N Engl J Med 1992;327:505-10.
• Wilson DE. Prostaglandins: their actions on the gastrointesti- nal tract. Arch Intern Med 1974;133:112-8.
• Tytgat GN, Offerhaus GJ, van Minnen AJ, et al. Influence of oral 15(R)-15-methyl prostaglandin E2 on human gastric mucosa. A light microscopic, cell kinetic, and ultrastruc- tural study. Gastroenterol 1986;90:1111-20.
• Nissan A, Zhang JM, Lin Z, et al. The contribution of inflam- matory mediators and nitric oxide to lipopolysaccharide- induced intussusception in mice. J Surg Res 1997;69:205-7.
• Pavri DR, Marshall DG, Armstrong RF, et al. Intrauterine in- tussusception: case report and literature review. Can J Surg 1983;26:376-8.
• Kobayashi N, Aida N, Nishimura G, et al. Acute gastric out- let obstruction following the administration of prostaglan- din: an additional case. Pediatr Radiol 1997;27:57-9.